Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramipril - sanofi aventis

Next Previous
X
Search
Drug Profile

Ramipril - sanofi aventis

Alternative Names: Acuvil; Altace; Carasel; Delix; HOE 498; Hypren; Pramace; Quark; Ramace; Triatec; Tritace; Unipril; Vesdil

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AstraZeneca; King Pharmaceuticals; Monarch Pharmaceuticals; Pfizer; Sanofi; University of California; University of Heidelberg
  • Class Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension
  • Phase III Renal failure
  • Phase II COVID 2019 infections
  • No development reported Ischaemic heart disorders
  • Discontinued Kidney disorders; Type 2 diabetes mellitus

Most Recent Events

  • 24 Aug 2023 Pfizer terminates phase-II RAMIC trial in COVID-2019 infections in USA due to low event rate and subsequent Emergency Use Authorization of therapies for COVID-19 infections (PO) (NCT04366050)
  • 26 Sep 2022 Phase-II development in COVID-2019 infections is ongoing in USA (PO) (NCT04366050)
  • 11 May 2020 Phase-II clinical trials in COVID-2019 infections in USA (PO) (NCT04366050)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top